Table 2.
Characteristic | No. (%) (n = 36) |
---|---|
Type of Progression | |
Systemic | 8 (22.2) |
Localized | 28 (77.8) |
Site of Progression | |
New only | 19 (52.8) |
Existing only | 14 (38.9) |
Both | 3 (8.3) |
Initial Treatment at Progression | |
Surgery | 12 (33.3) |
Radiation | 3 (8.3) |
Systemic | 15 (41.7) |
None/Hospice | 5 (13.9) |
Undecided | 1 (2.8) |
Type of Systemic Therapy after Progression | |
PD-1 | 11 (30.6) |
Continued | 8 (22.2) |
Switched | 3 (8.3) |
CTLA-4 | 3 (8.3) |
Combination PD-1/CTLA-4 | 1 (2.8) |
BRAF and/or MEK inhibitor | 5 (13.9) |
Clinical Trial* | 4 (11.1) |
Chemotherapy | 1 (2.8) |
Alive | |
Yes | 21 (58.3) |
No | 15 (41.7) |
Included trials (2) with ERK inhibitor and antibody-drug conjugate